

ECONOMIC COMPARISON OF THERAPEUTIC ALTERNATIVES FOR FIRSTLINE TREATMENT OF MULTIPLE MYELOMA

M.D. GIL-SIERRA¹, S. FENIX-CABALLERO¹, M.D.P. BRICEÑO-CASADO¹, M. DOMINGUEZ-CANTERO¹, E.J. ALEGRE-DEL REY¹.
¹HOSPITAL UNIVERSITARIO DE PUERTO REAL, PHARMACY, PUERTO REAL, SPAIN

1ISG-004

L01 - Cytostatics

BACKGROUND


- ✓ Combination of **daratumumab, bortezomib, melphalan and prednisone** with daratumumab in maintenance (DVMP-D) has been authorized in **first line of treatment** for patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation (NDMM-NoT).
- ✓ It makes necessary an economic comparison among different alternatives available, according to their **economic impact**.

AIM

To develop an **economic comparison** among therapeutic alternatives in **NDMM**

MATERIAL AND METHODS

Bibliographic research in **Medline** and **Embase**



Inclusion criteria

- ✓ **Treatment schemes:** daratumumab, lenalidomide, bortezomib, thalidomide or combinations
- ✓ **Authorized treatments** used in clinical practice
- ✓ **Randomized clinical trials phase II-III.**
- ✓ Articles in Spanish or English.
- ✓ Efficacy: **progression-free survival.**

Costs

- ✓ **Costs of the first-year treatment** → Notified laboratory sale price + 4% VAT - 7.5% rebate (Royal Decree-Law 8/2010)
- ✓ **Associated direct costs in first year:** added
- ✓ **Incremental costs with respect to reference:** **DVMP-D**

RESULTS

Results of systematic review: 593 studies → 9 trials selected → 7 drug combinations



Daratumumab+lenalidomide+dexamethasone excluded: non-using by National Health System (not funded)

Associated direct costs in first year: outpatients visit estimated at 167€



Costs of the first-year treatment

DVMP-D	Bortezomib+ melphalan+ Prednisone (VMP)	Melphalan+ Prednisone+ thalidomide with maintenance (MPT-T)	Lenalidomide+ dexamethasone in maintenance (RD)	Lenalidomide+ dexamethasone for 18 cycles (RD18)	Melphalan+ thalidomide+ prednisone (MTP)	Bortezomib+ lenalidomide+ dexamethasone with lenalidomide+ dexamethasone in maintenance (VRD-RD)
184,214€	44,435€	44,435€	81,520€	81,520€	77,209€	104,850€

Incremental costs



Most expensive scheme: DVMP-D
2^o most expensive: VRD-RD (-79,364€)



Cheapest scheme: MPT-T (-164,094€)
2^o cheapest: VMP (-139,779€)

CONCLUSION

1. There are **7 treatments** including daratumumab, lenalidomide, bortezomib or thalidomide for NDMM-NoT. **2.** The **most expensive schemes** for the **first year of treatment** are **DVMP-D** and **VRD-RD**; and the **cheapest** combinations are **MPT-T** and **VMP**.



<https://www.eahp.eu/25-1ISG-004>